Cargando…

Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility

Denosumab is a breakthrough biological drug approved by the Food and Drug Administration and European Medicines Agency for the treatment of osteoporosis in 2010. It is a fully human monoclonal antireceptor activator of nuclear factor kappa-B ligand antibody, which inhibits the activity of osteoclast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cavalli, Loredana, Brandi, Maria Luisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383338/ https://www.ncbi.nlm.nih.gov/pubmed/22745560 http://dx.doi.org/10.2147/TCRM.S7688

Ejemplares similares

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
por: Darbà, Josep, et al.
Publicado: (2015)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

Denosumab: mechanism of action and clinical outcomes
por: Hanley, D A, et al.
Publicado: (2012)

Osteoporosis in men: epidemiology and treatment with denosumab
por: Sidlauskas, Kristel M, et al.
Publicado: (2014)

A review of denosumab for the treatment of osteoporosis
por: Miyazaki, Tsuyoshi, et al.
Publicado: (2014)

The ever-expanding conundrum of primary osteoporosis: aetiopathogenesis, diagnosis, and treatment
por: Stagi, Stefano, et al.
Publicado: (2014)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab
por: Geusens, Piet
Publicado: (2009)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
por: Min, Yong-Ki
Publicado: (2015)

Alopecia areata after denosumab treatment for osteoporosis
por: Lyakhovitsky, Anna, et al.
Publicado: (2016)

Should denosumab treatment for osteoporosis be continued indefinitely?
por: Noble, Jane A., et al.
Publicado: (2021)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Denosumab, an effective osteoporosis treatment option for men
por: Kong, Sung Hye
Publicado: (2022)

Denosumab – a new medication in the treatment of postmenopausal osteoporosis
por: Słopień, Radosław, et al.
Publicado: (2017)

Treatment of osteoporosis with denosumab in patients with decreased kidney function
por: Svendsen, Ole Lander
Publicado: (2023)

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
por: Anastasilakis, Athanasios D, et al.
Publicado: (2012)

Effects of denosumab treatment in chronic liver disease patients with osteoporosis
por: Saeki, Chisato, et al.
Publicado: (2020)

Real World Experience of Denosumab Treatment in the Belfast Osteoporosis Service
por: Moran, CP, et al.
Publicado: (2019)

SUN-391 Denosumab Treatment of Patients with Osteoporosis and Idiopathic Hypercalciuria
por: Chu, Winston S, et al.
Publicado: (2020)

Cost-Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in South Korea
por: Kang, Jung-Yoon, et al.
Publicado: (2022)

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
por: Keaveny, Tony M, et al.
Publicado: (2014)

Periprosthetic bone loss: diagnostic and therapeutic approaches
por: Cavalli, Loredana, et al.
Publicado: (2014)

Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008)

Osteoporosis Therapy With Denosumab in Organ Transplant Recipients
por: Brunova, Jana, et al.
Publicado: (2018)

Persistence of Denosumab Therapy among Patients with Osteoporosis
por: Kobayashi, Kazuyoshi, et al.
Publicado: (2020)

Efficacy of Denosumab for Osteoporosis in Patients with Rheumatic Diseases
por: Kaneko, Kaichi, et al.
Publicado: (2022)

The efficacy of denosumab in Korean male patients with osteoporosis
por: Jeong, Chaiho, et al.
Publicado: (2022)

Long-term consequences of osteoporosis therapy with denosumab
por: Bandeira, Francisco, et al.
Publicado: (2022)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Clinical utility of denosumab for treatment of bone loss in men and women
por: Adler, Robert A, et al.
Publicado: (2011)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy
por: Zhang, Ning, et al.
Publicado: (2020)

Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
por: Johnson, Ben, et al.
Publicado: (2021)

Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review
por: Kendler, David L., et al.
Publicado: (2021)

Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review
por: Nargesi, Shahin, et al.
Publicado: (2022)

Denosumab for dialysis patients with osteoporosis: A cohort study
por: Kunizawa, Kyohei, et al.
Publicado: (2020)

Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab
por: Scheiner, S, et al.
Publicado: (2014)

Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment
por: Nakamura, Yukio, et al.
Publicado: (2017)

Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
por: Yanbeiy, Zeina A, et al.
Publicado: (2019)

Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis
por: Nakamura, Yukio, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_feem8iv0a4qk7lg9d3rlj9s42r